Business Context and Reporting Period
Company: MacroGenics, Inc. (MGNX)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer, including antibody-drug conjugates (ADCs) and multi-specific antibodies. A material event during the period was the completion of the sale of its Contract Development and Manufacturing Operations (CDMO) to Bora Pharmaceuticals on June 30, 2026. These operations are now reported as discontinued operations.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Total Revenue | $32.8 million | $39.6 million |
| Net Income (Loss) | $19.5 million | $(17.3) million |
| Net Loss from Continuing Operations | $(69.6) million | $(110.9) million |
| Net Income from Discontinued Operations | $89.2 million | $93.7 million |
| Cash and Cash Equivalents (End of Period) | $113.9 million | $113.9 million |
| Marketable Securities | $59.4 million | $59.4 million |
| Total Assets | $345.4 million | $345.4 million |
| Total Liabilities | $302.5 million | $302.5 million |
| Stockholders' Equity | $42.9 million | $42.9 million |
Debt and Liquidity: The company has no traditional debt but carries a significant "Liability related to future royalties" of $178.1 million ($15.0 million current, $163.2 million non-current) resulting from a royalty monetization arrangement with Sagard Healthcare Partners. Management states that current resources, combined with proceeds from the CDMO sale and anticipated milestones, support a cash runway through 2028.
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased 375% year-over-year for the quarter (from $6.9M to $32.8M) and 184% for the six-month period. This was driven primarily by a $24.5 million regulatory milestone from Sanofi (TZIELD) and increased royalty revenue from ZYNYZ sales.
- Discontinued Operations: The sale of the CDMO business resulted in a net gain of $86.1 million recognized in discontinued operations, turning a net loss from continuing operations into a net income for the quarter.
- Royalty Monetization Extinguishment: The company amended its royalty sale agreement with Sagard, triggering a non-cash loss on extinguishment of $52.8 million in continuing operations.
- Operating Expenses: Research and Development (R&D) expenses decreased slightly year-over-year (down 5% for the quarter) due to the discontinuation of the vobra duo program and reduced costs for lorigerlimab, partially offset by increased spending on MGC026 and MGC028.
Guidance, Outlook, and Risks
Outlook: Management anticipates that cash, cash equivalents, marketable securities, the $119.6 million received from the Bora sale, and upcoming milestones (including $24.5M from Sanofi and $10.0M from Gilead) will fund operations through 2028. The company is executing cost-saving measures to extend its financial runway.
Key Risks and Contingencies:
- Manufacturing Reliance: Following the CDMO sale, MacroGenics no longer operates its own GMP facility and relies entirely on third parties (including Bora) for clinical and commercial manufacturing. Risks include capacity constraints, quality issues, or contract disputes.
- Capital Requirements: Future success depends on the ability to raise additional capital or secure new collaborations. Failure to do so could require delaying or eliminating R&D programs.
- Regulatory and Clinical Uncertainty: Outcomes of ongoing clinical trials for product candidates (MGC026, MGC028, lorigerlimab) remain uncertain.
- Royalty Liability: The company has a substantial liability related to future royalties paid to Sagard, which impacts net income through non-cash interest expense.
Investor Verification Checklist
- CDMO Sale Proceeds: Verify the finalization of the $119.6 million cash proceeds from the Bora sale and any post-closing working capital adjustments.
- Sanofi Milestone Payment: Confirm the receipt of the $24.5 million regulatory milestone payment from Sanofi, currently recorded as a receivable.
- Gilead Option Exercise: Monitor the receipt of the $10.0 million payment from Gilead for the exercise of the First Research Program option (subsequent event).
- Royalty Monetization Terms: Review the amended terms with Sagard, specifically the new threshold amount (1.70x to 2.0x purchase price) and the impact of the $52.8 million extinguishment loss on future earnings.
- Manufacturing Transition: Assess the operational stability of the transition to third-party manufacturing and the terms of the new supply agreement with Bora.